EvolusEOLS
Recorded

Evolus 2026 Stifel Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration33 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Annabel SamimyAnalyst

Okay. All right. Good afternoon, everyone. Welcome to the Evolus session. It is our pleasure to have Dave Moatazedi, CEO. We actually have the whole team here. Dave Moatazedi, CEO, Rui Avelar, CMO, and Tatjana Mitchell, CFO. As you know, Evolus is an aesthetics-only company, coining performance beauty, I guess, is what you phrased. It is our pleasure to have you here after six, almost seven years after your first launch of Jeuveau. Maybe you can first give us the overview of the company, and we can launch into Q&A.

David MoatazediCEO and President

Sure. Thank you again for having us. It is great to be here. Just a little bit of background on Evolus. We have been a commercial stage company, as you pointed out, for the last seven years. Our flagship product, Jeuveau, has really led the way for us as we established our beachhead in the U.S. We are the fastest-growing toxin for a handful of years in the U.S., and we are the first company since the market leaders arrived to achieve a double-digit market share in the space. Over the last 18 months, we have diversified the company in multiple ways beyond a single product. One is we introduced a new line of hyaluronic acid fillers, brand new to the entire world. We introduced it first here in the U.S., called Evolysse.

David MoatazediCEO and President

Just the first two formulations in our first year on the market, a couple more coming over the next few years. We have also built out our international business, which is now representing a bigger portion of our overall revenue mix. We said we expect it to be 10% of revenue this year. In that international business, we have also expanded with our HA products. We call them the Estyme line of products that we introduced in Europe in the second quarter. We are just a couple quarters into that launch as well. A lot of really exciting growth opportunities for the company, which enable us to partner more closely with clinicians around our cash pay platform. We have seen really healthy growth as you look at the third quarter across all of those areas. We are excited about the future, I guess would be the last thing.

David MoatazediCEO and President

We have a pipeline that has three new products we plan to introduce over the next four years, and we think all of those present a meaningful opportunity to partner more closely with clinicians as our portfolio starts to capture the key areas that they are using these injectable products. That makes the overall portfolio value proposition more meaningful.

Annabel SamimyAnalyst

Great. So, maybe before we start anything, you can talk about the state of the aesthetics market, maybe characterize the aesthetics demand, particularly the demand that you're seeing in the toxins versus the fillers. We hear a lot of conflicting statements from different parties, so maybe you can give us your take on it.

David MoatazediCEO and President

Yeah. I think we're in a very healthy aesthetic market. Start with the consumer. You have consumer demand for health, wellness, beauty categories. You look across the sectors, it's been very strong this year. Going down to our target demographic, which is a consumer earning about $100,000 or more in household income, that consumer is very strong, and we don't see that slowing. You saw that evidenced by the toxin market growing, we believe, sort of in this upper single-digit range in the third quarter. Both market leaders reported positive growth in their toxin business. I think those are all very strong signs that the market continues to be really healthy. Then beyond that, the filler market was really the question last year.

David MoatazediCEO and President

It had a couple challenging years, driven by some negative consumer sentiment, and that was compounded by a bit of slowing in demand as well. What we're seeing is that market starting to turn around. I would say it's stabilized this year.

David MoatazediCEO and President

It's roughly flat, growing maybe slightly. Obviously, we have a launch product in that market.

David MoatazediCEO and President

We're approaching the mid-single-digit market share, so we're seeing really healthy growth. I think it's a very positive sign that the market's now turning in HAs, and we believe that sets up really nicely for the next several years.

Annabel SamimyAnalyst

Just on the filler growth, is it more a factor of consumer health, or is it a factor of changing trends? Now going into it a couple years as it's turning around, what do you think is coming out of that?

David MoatazediCEO and President

Yeah. There's likely a few things happening. Number one is the consumer is looking for a more natural look. What that means is when they're going in and they're getting hyaluronic acid products, which is still the number one use of fillers or hyaluronic acid gels, they're just getting less volume per treatment than what you were seeing post-COVID in the boom, where patients were coming in and getting multiple syringes. So, we believe that in actual patient volume, the market might be up closer to mid to high single digits.

David MoatazediCEO and President

It's in volume of units that you're seeing the market call roughly flattish. So, that's a really positive sign. The second thing we're seeing consistently as we're talking to clinics and we're doing research is that the GLP-1 patient is absolutely entering the clinic. They're referencing volume loss as one of the key areas that they're particularly concerned about. Obviously, HAs are the only solution that provide an immediate replacement of volume in the clinic. So, that positions HAs really well to benefit from that. Lastly, it's worth noting that Evolysse is still the only hyaluronic acid with a mention of GLP-1s in our label.

David MoatazediCEO and President

That's really important, not only because we can market that to the consumer, but when you think about our cash pay co-branded media strategy, where as you purchase more, you get our investment back into the clinic to advertise, we now have billboards and different media solutions around Evolysse that target that segment. We've heard very positive feedback on that. It's still early days, but we know this is a big tailwind for the category. To be able to invest early days as we build the Evolysse brand is meaningful for these accounts.

Annabel SamimyAnalyst

Yeah. One of the things obviously is a new product. It's clear that you're going to have above-market growth, but you've been able to maintain above-market growth for not only Evolysse, because you're launching, but because of with Jeuveau, which is six or seven years, I've lost track, it's six or seven years already in the market. How have you been able to maintain that above-market growth? It's pretty surprising for a company.

David MoatazediCEO and President

Yeah. Well, I'd start with Jeuveau's an incredible product.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day